Immudex ApS

Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex provides MHC Dextramers for the monitoring of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide. Immudex’s MHC Dextramer® products are utilized for the quantification or sorting of antigen-specific T cells in life science research, in vitro diagnostics, as well as the development of immunotherapeutics and vaccines. The primary focus is research-use-only products for the immune monitoring of immunotherapy development, and monitoring of CMV cellular immunity in transplant and other immune-deficient patients. In Europe, the CE-marked Dextramer CMV Kit is approved for in vitro diagnostic use, for the quantification of CMV-specific T cells. Our soon-to-be released DNA tagged Dextramer reagents enable massive multiplexing of antigen